Anesthesia · Neuromuscular BlockadeRegulatory Approvalregulatorymid-term

FDA Accepts Sugammadex Sodium Application from Mankind Pharma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 6:31:23 AM

Assessment confidence: 53% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's acceptance of Sugammadex Sodium from Mankind Pharma is a significant regulatory milestone that could disrupt the neuromuscular blockade market. This development necessitates close monitoring of competitive dynamics and potential responses from established players in the sector. Regulatory context from FDA (FDA AP — SUGAMMADEX SODIUM (ORIG)) supports the near-term read. Assessment grounded in 14 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and prepare for competitive responses from existing neuromuscular agents. The strongest clinical anchor is A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In nmus rehab, 8 regulatory and 4 competitive items passed relevance filtering for Mankind Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval (Humanexa Signals) — sub-indication match (nmus rehab); entity match (sugammadex sodium). Secondary pressure from Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311). This acceptance may position Mankind Pharma to compete in the neuromuscular blockade market, which includes established players.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SUGAMMADEX SODIUM (ORIG) (FDA). Entity match (mankind pharma); Regulatory pathway relevance (nda). The acceptance of the application indicates a pathway towards potential approval, but the final decision will determine compliance and market entry timelines.

Key Risks

Elevated medium regulatory exposure for Mankind Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, Sugammadex Sodium could capture market share from existing neuromuscular agents, impacting revenue streams for competitors.
Portfolio teams should assess the potential market impact and prepare for competitive responses from existing neuromuscular agents.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the application and any subsequent FDA decisions regarding Sugammadex Sodium.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval would change the regulatory/clinical read.
Outcome from Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311) would change the regulatory/clinical read.

Supporting Evidence

FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (mankind pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Evaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
FDA Grants Approval for Sugammadex Sodium under ANDA214368
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
FDA Approves Sugammadex Sodium for Gland Pharma
Humanexa Signalsmedium relevance
Entity match (sugammadex sodium)

A comprehensive review on Jiao-tai-wan: Traditional application, pharmacokinetics, and therapeutic mechanisms in multiple disorders.
PubMedmedium relevance
Mechanism alignment (IO )
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
An integrated approach combining transcriptomics, network pharmacology, and experimental validation are used to investigate the mechanism of Lonicerae Japonicae Flos and Forsythiae Fructus extracts ag
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mankind Pharma
Sugammadex Sodium

Commercial impact

medium

If approved, Sugammadex Sodium could capture market share from existing neuromuscular agents, impacting revenue streams for competitors.

Regulatory impact

medium

The acceptance of the application indicates a pathway towards potential approval, but the final decision will determine compliance and market entry timelines.

What to watch

Monitor the progress of the application and any subsequent FDA decisions regarding Sugammadex Sodium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.